John F. Crowley
John F. Crowley is the Chairman and CEO of Amicus Therapeutics. John’s involvement with biotechnology stems from the 1998 diagnosis of two of his children with Pompe disease—a severe and often fatal neuromuscular disorder. In his drive to find a cure for them, he left his position at Bristol-Myers Squibb and became an entrepreneur as the Co-founder, President and CEO of Novazyme Pharmaceuticals, a biotech start-up conducting research on a new experimental treatment for Pompe disease (which he credits as ultimately saving his children’s lives). In 2001, Novazyme was acquired by Genzyme Corporation and John continued to play a lead role in the development of a drug for Pompe disease as Senior Vice President, Genzyme Therapeutics.
There Is No Place For Bias, Mistrust Or Underrepresentation In Healthcare
How can healthcare leaders bridge the gap between minority communities and the healthcare industry—and achieve scientific justice for all?
- Advertisement -
- Advertisement -
FEATURED CONTENT
New Poll: CEOs Find Challenges In Using Customer Data To Drive Innovation
Ability to harness and sort through data for meaningful insights remains a hurdle, many say. “The key is...finding what is actually relevant.”
SUBSCRIBE TO CHIEF EXECUTIVE
Sign Up to Receive Chief Executive Magazine
Chief Executive’s publications are designed to help CEOs do their jobs better and run their businesses more effectively. Subscribe here.
CEO CONFIDENCE INDEX
In Poll, Majority of CEOs Say Hybrid Work Is Here to Stay for 2022. Full Virtual? Not so Much
Almost all the CEOs we surveyed in May say they will work in at least partially hybrid mode for the rest of the year—versus just 7 percent who said they'd be fully remote.